Medicenna Therapeutics

She will guide our IL-2 superagonist platform and #MDNA113 (our tumour-targeted, conditionally activated, anti-PD-1-IL-2 bifunctional superkine) toward a planned IND in H2 2026. She will also oversee our Phase 3-ready bizaxofusp program for recurrent #Glioblastoma. $MDNAF $MDNA.TO

Dr. Ibrahim formerly served as VP of Global Clinical Development, Oncology at @Merck. In this role, she led the strategic direction and pivotal global registration studies for pembrolizumab across multiple tumour types and combination regimens. $MDNAF $MDNA.TO

We are pleased to welcome Dr. Nageatte Ibrahim as Chief Medical Officer (fractional) at Medicenna. With >20 years of oncology experience, her leadership will be pivotal as we advance our immunotherapy pipeline. $MDNAF $MDNA.TO

Want to dive deeper into the #MDNA113 data? Scan the codes below to read an independent Substack deep-dive on our mechanism, or download our latest corporate presentations ahead of #AACR26.

At Medicenna, we're building the solution. MDNA113 is designed to decouple systemic transport from local immune activation. Conditionally activated & tumor-anchored to IL-13Rα2 (driving aggressive tumors in >2M patients/yr), it enables localized, sustained engagement. On track for First-in-Human (FIH) H2 2026!  $MDNAF #AACR26

As we prep to share our latest #MDNA113 data at #AACR26, the #ImmunoOncology space is officially heating up! There is a MASSIVE push in pharma for PD-1 bispecifics. We're seeing >$43 BILLION in recent combined transaction value in this space alone. $MDNAF $MDNA.TO

Unlocking immunologically "cold" tumors is one of oncology's greatest challenges. We are thrilled to announce that Medicenna will present highly anticipated preclinical data for our first-in-class IL-2-PD-1 Superkine, #MDNA113, at #AACR26 in San Diego! Read the full PR here: ir.medicenna.com/news-releases/… $MDNAF $MDNA.TO #Biotech #Oncology #Immunotherapy #CancerResearch (Disclaimer: MDNA113 is investigational. Post contains forward-looking statements. See SEDAR/SEC filings for risks).

At Medicenna, this macro trend perfectly frames our mission. We are actively engaging potential partners to commercialize MDNA55 (bizaxofusp), our Phase-3-ready therapy for recurrent #GBM. The spotlight is back on CNS innovation! $MDNAF

As industry analysts note, we are seeing "franchise formation." As large companies build out multi-asset brain tumor portfolios, Phase-3-ready programs addressing high-unmet-need indications—like recurrent #GBM—naturally become highly relevant.

The #NeuroOncology space is heating up! Servier’s ~$2.5B acquisition of Day One Biopharma is a major milestone. While entirely independent of Medicenna, it sends a powerful strategic signal about renewed, structural investment in CNS tumors. $MDNAF #Biotech

$MDNAF $MDNA.TO That’s a wrap from Boston!  Incredible reception at the Glioblastoma Drug Development Summit for CEO Dr. Fahar Merchant’s presentation on bizaxofusp. The clinical takeaways: ✔️ "Trojan Horse" delivery bypasses the BBB ✔️ Favorable safety profile in 118 patients ✔️ Efficacy: As shown below, DOUBLING the median survival rate with a single dose in unresectable recurrent GBM (where there are no other options for these patients). View our newly uploaded presentation deck here: ir.medicenna.com/events/event-d…  #Biotech #Oncology #GBMSummit

$MDNAF $MDNA.TO HAPPENING TODAY (10 AM EST) Our CEO Dr. Fahar Merchant takes the stage at the 7th Annual Glioblastoma Summit in Boston. He will present data on surmounting barriers in non-resectable recurrent #Glioblastoma (rGBM) with a single treatment of Bizaxofusp. #biotech #Oncology

Correction: The Glioblastoma Development Summit is actually today, February 19th! Catch Dr. Fahar Merchant on stage in Boston shortly to discuss Bizaxofusp (MDNA55). See you there!

We are moving from Biology Outpaced to Execution Optimized. Get up to speed before tomorrow's GBM Summit presentation: 🔗 Read the independent Substack deep-dive: davidbakke.substack.com/p/from-biology… 🔗 Download the corporate deck: ir.medicenna.com/news-releases/…

Today at 10:00 am EST, at the 7th Annual GBM Summit, $MDNAF $MDNAF.TO CEO Dr. Fahar Merchant will present clinical updates on bizaxofusp. Before he takes the stage, let's prep on the science. Why have 30 years of brain cancer breakthroughs failed? A quick primer ⬇️🧵 1/4